Navigation Links
NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
Date:3/19/2009

CLEVELAND, March 19 /PRNewswire-FirstCall/ --DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that a NASDAQ Hearings Panel (the "Panel") has granted the Company's request for continued listing on The NASDAQ Capital Market, subject to the condition that, on or before June 1, 2009, the Company must evidence compliance with the minimum $2.5 million stockholders' equity requirement or one of the alternative criteria for continued listing. The Panel's determination follows a hearing held on January 8, 2009 at which the Company presented its plan to regain compliance. The Company is taking steps to comply with the terms of the Panel's decision. However, in the event that the Company is unable to demonstrate compliance with all requirements for continued listing by June 1, 2009, its common shares would be subject to delisting from The NASDAQ Capital Market.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; delisting of the Company's common shares from the Nasdaq Capital Market; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
2. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
3. The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo
4. Pharmacyclics Receives Nasdaq Notification
5. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
6. Cell Therapeutics to Resume Trading on MTA and NASDAQ
7. The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders
8. EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF)
9. Alfacell Announces Receipt of NASDAQ Panel Decision
10. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
11. NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... , ... Medical lab testing through hospitals and other traditional methods ... will take days to arrive to the end customer, having to travel through medical ... lab tests, bypassing the cost and delay of traditional means. Now all employees of ...
(Date:1/21/2017)... ... 2017 , ... Salveo for life, a company that distributes an effervescent lime-flavored ... States as part of its presence to expand its market reach. , Using a ... productions of nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Seamild, the ... on the futuristic vision of its owner and founder. As Oat is recognized globally ... to everybody he knows personally as he believes it is a move to sow ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s ... electrifying line-up of events for its annual meeting “Coming Home 2017,” an activity-packed ... “Coming Home 2017” will be held on Friday January 27 through Sunday, January ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa ... in Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three ... medicine and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
(Date:1/23/2017)... , Jan. 23, 2017 LifeVac, the ... a blocked airway and prevented choking deaths, welcomes ... advocate to the LifeVac team as Official Spokesperson. ... join the LifeVac team," said Arthur Lih , ... to represent LifeVac and his mission to raise awareness ...
(Date:1/23/2017)... 23, 2017 Research and Markets has announced the ... - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... trends to identify the investment opportunities Market forecasts till ... Key market trends across the business segments, Regions and Countries ...
Breaking Medicine Technology: